Your browser is no longer supported. Please, upgrade your browser.
Settings
PHGE BiomX Inc. daily Stock Chart
PHGE [AMEX]
BiomX Inc.
Index- P/E- EPS (ttm)-4.34 Insider Own3.60% Shs Outstand22.97M Perf Week-1.48%
Market Cap143.52M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float18.40M Perf Month1.02%
Income-33.00M PEG- EPS next Q- Inst Own26.50% Short Float0.11% Perf Quarter7.58%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio1.18 Perf Half Y8.76%
Book/sh3.20 P/B1.86 EPS next Y- ROA- Target Price- Perf Year-41.82%
Cash/sh2.90 P/C2.06 EPS next 5Y- ROE- 52W Range4.52 - 11.50 Perf YTD-38.46%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-48.17% Beta-
Dividend %- Quick Ratio20.50 Sales past 5Y- Gross Margin- 52W Low31.86% ATR0.23
Employees73 Current Ratio20.50 Sales Q/Q- Oper. Margin- RSI (14)44.80 Volatility3.32% 3.10%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.13 Prev Close6.20
ShortableYes LT Debt/Eq0.00 EarningsAug 13 BMO Payout- Avg Volume17.61K Price5.96
Recom- SMA20-4.17% SMA50-1.17% SMA200-12.62% Volume2,274 Change-3.87%
Oct-21-20 06:30AM  
Oct-05-20 06:30AM  
Sep-10-20 04:30PM  
Sep-02-20 06:30AM  
Aug-13-20 06:30AM  
Aug-12-20 12:17PM  
Aug-06-20 07:00AM  
May-14-20 06:30AM  
May-11-20 05:00PM  
Apr-07-20 04:05PM  
Mar-31-20 06:30AM  
Mar-26-20 06:30AM  
Mar-20-20 08:00AM  
Feb-17-20 07:00AM  
Dec-02-19 07:30AM  
Nov-12-19 07:30AM  
07:25AM  
Nov-04-19 05:38PM  
07:30AM  
BiomX Inc., a clinical stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), liver, primary sclerosing cholangitis, and cancer. The company's lead product candidate BX001, which is in phase I that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type; BX002, a therapeutic phage product to treat IBD; BX003, targets bacteria associated with progressive liver disorder (PSC), a rare inflammatory liver disease; and CRC, targets strains of bacteria found in colorectal cancer tumors. The company has license agreement collaboration with The Weizmann Institute of Science to develop, test, manufacture, produce, and sell microbiome-based therapeutic product candidate; Takeda, develops formulations for phage therapy manufacturing intermediates and for the final form to be administered; Keio University and JSR Corporation, a set of bacterial targets for the development and commercialization of phage therapies to treat IBD; and Janssen Research & Development, LLC to utilize XMarker microbiome-based biomarker discovery platform. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OrbiMed Israel BioFund GP LimiDirectorDec 19Buy8.903,50031,1502,313,489Dec 20 01:58 PM
Chimovits ErezDirectorDec 19Buy8.903,50031,1502,313,489Dec 20 01:56 PM
OrbiMed Israel BioFund GP LimiDirectorDec 18Buy8.935004,4652,309,989Dec 20 01:58 PM
Chimovits ErezDirectorDec 18Buy8.935004,4652,309,989Dec 20 01:56 PM
Chimovits ErezDirectorDec 11Buy8.925,40048,1682,309,489Dec 12 06:54 PM
OrbiMed Israel BioFund GP LimiDirectorDec 11Buy8.925,40048,1682,309,489Dec 12 06:52 PM
Chimovits ErezDirectorDec 10Buy8.753,40029,7502,304,089Dec 12 06:54 PM
OrbiMed Israel BioFund GP LimiDirectorDec 10Buy8.753,40029,7502,304,089Dec 12 06:52 PM
OrbiMed Israel BioFund GP LimiDirectorDec 09Buy8.686,00052,0802,300,689Dec 09 08:30 PM
Chimovits ErezDirectorDec 09Buy8.686,00052,0802,300,689Dec 09 08:19 PM
OrbiMed Israel BioFund GP LimiDirectorDec 06Buy8.008006,4002,294,689Dec 09 08:30 PM
Chimovits ErezDirectorDec 06Buy8.008006,4002,294,689Dec 09 08:19 PM
OrbiMed Israel BioFund GP LimiDirectorDec 05Buy7.993,40027,1662,293,889Dec 09 08:30 PM
Chimovits ErezDirectorDec 05Buy7.993,40027,1662,293,889Dec 09 08:19 PM
GROSSMAN JONASDirectorNov 20Buy8.001,40011,2066,500Nov 20 04:32 PM
GROSSMAN JONASDirectorNov 19Buy7.574,10031,0495,100Nov 20 04:32 PM
GROSSMAN JONASDirectorNov 18Buy6.991,0006,9891,000Nov 20 04:32 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.